Amgen opened a Singapore affiliate in December 2015 to market its innovative medicines for patients suffering from serious illnesses. This will further strengthen Amgen’s capabilities to address the region’s growing healthcare needs and provide treatments for patients in Singapore.
Amgen’s initial priorities in Singapore will include:
Amgen’s medicines treat serious illnesses and typically address diseases with a limited number of treatment options. Products currently approved in Singapore include: Prolia® (denosumab), XGEVA® (denosumab), Vectibix® (panitumumab), NEUPOGEN® (filgrastim) and Neulastim® (pegfilgrastim).
By working closely with the Health Sciences Authority on multiple drug registrations, Amgen is working towards ensuring more of its vital medicines are made available to patients in Singapore as soon as possible.
Amgen Singapore Fact Sheet